Back to Careers

Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1

Back to Careers

Hanadie served on a CEO panel with a group of portfolio companies for Bascom Ventures (part of Alumni Ventures)

Back to Careers

CIRM Awards Juvena a $3.9M TRAN1 Grant to Advance JUV-161 for Myotonic Dystrophy Type 1 (DM1)

Back to Careers

CEO Dr. Yousef Represents Juvena at Longevity Summit 2021

Back to Careers

CEO Dr. Hanadie Yousef Presents at UC Berkeley’s Slam Seminar Series Nov. 2019

Back to Careers

CEO Dr. Hanadie Yousef Interviewed for Translating Aging Podcast, “The Cures Within Us”

Back to Careers

Juvena Therapeutics Presents at the Muscular Dystrophy Association Insights in Research Investor Summit

Back to Careers

Juvena Therapeutics Presents at the International Longevity Alliance Conference Workshop Feb 2021